23G玻璃体切除术后老年糖尿病患者EX-PRESS青光眼引流器植入的评估
Evaluation of EX-PRESS glaucoma implant in elderly diabetic patients after 23G vitrectomy.
作者信息
Lyssek-Boroń Anita, Wylęgała Adam, Dobrowolski Dariusz, Kowalczyk Ewelina, Polanowska Katarzyna, Wylęgała Edward
机构信息
Department of Ophthalmology with Pediatric Unit, Trauma Center, Santa Barbara Hospital, Sosnowiec.
Department of Ophthalmology, Ophthalmology Clinic, Medical University of Silesia, District Railway Hospital, Katowice, Poland.
出版信息
Clin Interv Aging. 2017 Apr 10;12:653-658. doi: 10.2147/CIA.S128618. eCollection 2017.
PURPOSE
The most frequent qualifications for pars plana vitrectomy (PPV) in diabetic patients include recurrent hemorrhage into the vitreous body chamber and vitreoretinal proliferation, also with traction retinal detachment. The aim of this study was to evaluate the effectiveness of EX-PRESS implant for the treatment of secondary glaucoma in elderly diabetic patients following PPV 23G with silicon oil or SF6 gas endotamponade.
MATERIALS AND METHODS
This retrospective analysis comprised 18 patients (19 eyes). We applied EX-PRESS implants in 9 patients with neovascular glaucoma (NVG) and in 10 patients with non-NVG. All patients had earlier history of diabetes and vitrectomy 23G for diabetic complications. Intraocular pressure (IOP) was measured and compared before; 7 days; 1, 3, 6, and 12 months; and a year after the surgery.
RESULTS
Application of the implant exhibited a lowering effect on IOP. After 1 month, 53% of patients had IOP values beyond 22 mmHg, while 86% after 1 year.
CONCLUSION
The implant can be used to treat both NVG and non-NVG in diabetic patients following PPV.
目的
糖尿病患者行玻璃体平坦部玻璃体切除术（PPV）最常见的适应证包括玻璃体积血复发、玻璃体视网膜增殖以及牵引性视网膜脱离。本研究的目的是评估EX-PRESS植入物在硅油或SF6气体眼内填充的23G PPV术后治疗老年糖尿病患者继发性青光眼的有效性。
材料与方法
本回顾性分析纳入18例患者（19只眼）。9例新生血管性青光眼（NVG）患者和10例非NVG患者植入EX-PRESS植入物。所有患者既往均有糖尿病史，并因糖尿病并发症接受过23G玻璃体切除术。分别于术前、术后7天、1、3、6、12个月及1年测量并比较眼压（IOP）。
结果
植入物对IOP有降低作用。术后1个月，53%的患者IOP值超过22 mmHg，而术后1年这一比例为86%。
结论
该植入物可用于治疗PPV术后糖尿病患者的NVG和非NVG。
Zotero 插件